ReviewIn vitro cellular & developmental biology. Plant : journal of the Tissue Culture Association2021
Current status and prospects of plant genome editing in Australia.
Review in In vitro cellular & developmental biology. Plant : journal of the Tissue Culture Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Market introduction of plant varieties and products with gene-edited traits.GM crops & food · 2026Review
- Beyond GMOs: transgene-free gene-edited crops for global food security.Frontiers in plant science · 2026Review
- Promoter replacement by genome editing creates gain-of-function traits in Arabidopsis.Plant biotechnology journal · 2025Article
- An accelerated transgene-free genome editing system using microparticle bombardment of sorghum immature embryos.aBIOTECH · 2025Article
- Future of durum wheat research and breeding: Insights from early career researchers.The plant genome · 2025Review
- Application of CRISPR/Cas9-mediated gene editing for abiotic stress management in crop plants.Frontiers in plant science · 2023Review
- GMOs or non-GMOs? The CRISPR Conundrum.Frontiers in plant science · 2023Review
- Genetically modified organisms: adapting regulatory frameworks for evolving genome editing technologies.Biological research · 2022Review
- Enabling Genome Editing for Enhanced Agricultural Sustainability.Frontiers in genome editing · 2022Article
- Synthetic and Engineering Biology in Australia: Advances in Infrastructure, Coordination and Impact.Engineering biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant genome editing, particularly CRISPR-Cas biotechnologies, has rapidly evolved and drawn enormous attention all around the world in the last decade. The cutting-edge technologies have had substantial impact on precise genome editing for manipulating gene expression, stacking gene mutations, and improving crop agronomic traits. Following the global trends, investigations on CRISPR-Cas have been thriving in Australia, especially in agriculture sciences. Importantly, CRISPR-edited plants, classified as SDN-1 organisms (SDN: site-directed nuclease), have been given a green light in Australia, with regulatory bodies indicating they will not be classified as a genetically modified organism (GMO) if no foreign DNA is present in an edited plant. As a result, genome-edited products would not attract the onerous regulation required for the introduction of a GMO, which could mean more rapid deployment of new varieties and products that could be traded freely in Australia, and potentially to export markets. In the present review, we discuss the current status and prospects of plant genome editing in Australia by highlighting several species of interest. Using these species as case studies, we discuss the priorities and potential of plant genome editing, as well as the remaining challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.